Chandra Bhagat (542934)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Operates in the pharmaceutical sector, which has long-term structural demand in India.
• Latest quarter sales of ₹26 Cr provide some operating scale relative to the ₹52 Cr market cap.
• Profit decline of -33.82% is less severe than the -60.64% sales decline, hinting at some cost discipline.
• ROCE is positive at 6%, so the business is not completely destroying operating capital.

Concerns

• Sales growth of -60.64% and latest quarter net profit of ₹0 Cr indicate severe business deterioration.
• P/E of 48.02 offers no margin of safety while earnings are falling.
• Piotroski F-Score of 3/9 points to weak fundamental health.
• No dividend, undisclosed promoter holding, and undisclosed book value create opacity for minority shareholders.

AI Analysis

At first glance, Chandra Bhagat looks like the kind of micro-cap that Benjamin Graham would circle with suspicion, not excitement. The price is ₹69.39, near the top of its 52-week range, yet the business is shrinking: sales are down 60.64%, and profits have fallen 33.82%. The latest quarter shows revenue of ₹26 crore and net profit of approximately zero. Paying a P/E of 48.02 for a company whose earnings are evaporating is not investing; it is hoping. Graham taught me to demand a margin of safety, and there is none here. Return on capital employed is only 6%, barely above a bank fixed deposit. A mediocre business trading at a rich multiple with deteriorating fundamentals is a classic value trap. The Piotroski F-Score of 3 out of 9 reinforces my concern: on this fundamental health check, the company fails on most counts. There is no dividend to compensate while I wait, and promoter holding and book value are not disclosed. In pharma, a company with a real moat should show stable margins and pricing power; this one shows neither. With a market cap of just ₹52 crore, any small absolute loss can destroy significant shareholder value. I would not touch this unless profit trend reverses, sales stop falling, and management demonstrates transparent capital allocation. The stock has moved from ₹29.70 to ₹69.39, but price movement is not evidence of business quality. In Buffett's words, it is far better to buy a wonderful business at a fair price than a poor business at a wonderful price. Here we have a rich price for a deteriorating business. I will stay on the sidelines.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer